- Report
- April 2023
- 180 Pages
Global
From €2142EUR$2,400USD£1,863GBP
€2678EUR$3,000USD£2,329GBP
- Report
- April 2023
- 137 Pages
Global
From €5356EUR$6,000USD£4,657GBP
€6695EUR$7,500USD£5,821GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1964EUR$2,200USD£1,708GBP
€2455EUR$2,750USD£2,135GBP
- Report
- February 2022
- 210 Pages
Global
From €5356EUR$6,000USD£4,657GBP
€6695EUR$7,500USD£5,821GBP
- Report
- April 2023
- 115 Pages
Global
From €4240EUR$4,750USD£3,687GBP
- Report
- August 2022
- 111 Pages
Global
From €4240EUR$4,750USD£3,687GBP
- Report
- June 2022
- 120 Pages
Global
From €4240EUR$4,750USD£3,687GBP
- Report
- May 2024
- 139 Pages
Global
From €5802EUR$6,499USD£5,044GBP
- Report
- May 2024
- 134 Pages
Global
From €5802EUR$6,499USD£5,044GBP
- Report
- September 2024
- 82 Pages
Japan
From €3124EUR$3,500USD£2,717GBP
- Report
- September 2024
- 82 Pages
Japan
From €3124EUR$3,500USD£2,717GBP
- Report
- August 2024
- 80 Pages
Japan
From €3124EUR$3,500USD£2,717GBP
- Report
- May 2024
- 185 Pages
Global
From €4017EUR$4,500USD£3,493GBP
- Report
- April 2024
- 190 Pages
Global
From €4017EUR$4,500USD£3,493GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more